Revenue

With a €1.5B capital raise backed by governments and strategic giants, Eutelsat is fueling its unique hybrid satellite network to compete in the new space race.

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

SEALSQ appoints public-private partnership veteran Rolf Gobet to lead its new Geneva Quantum Center, a key move in a well-funded race against quantum threats.

New AI voice agents promise to capture millions in lost revenue for med spas by working after hours. Is this the future of the aesthetic care market?

Yum China's massive share buyback isn't just about rewarding investors. It's a calculated move signaling financial dominance in a complex market.

Malaysia's Treasure Global secures fresh capital, but a brutal market reaction and high cash burn raise questions about its super app's future.

Houston's Spotlight Energy closes its acquisition of PathPoint, creating a natural gas giant poised to enhance reliability across North American markets.

A new startup is betting a premium AI desktop calendar can cure our smartphone addiction. But is another screen really the answer to too much screen time?

A South Korean firm has solved a hidden flaw in industrial magnets, promising a leap in efficiency for battery, recycling, and mining industries.

A new partnership combines 3D depth with panoramic visuals, creating an unparalleled movie experience. But is it enough to win the premium cinema war?

A $277M secondary offering sees MIAX shareholders cash in, but the company itself isn't taking any money. Here’s what that says about its financial power.

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

Lument Finance Trust's latest dividend boasts an attractive yield, but recent adjustments raise questions about the health of commercial real estate.

Health Union's new platform for ATTR amyloidosis isn't just a website. It's a strategic blend of patient support and business innovation. Here's why.

With a $2.5B boost from Blue Owl, Finance of America aims to move beyond reverse mortgages and reshape how millions of retirees access their home equity.

AMC's key governance reforms failed despite 90% voter support, stymied by low turnout. Meanwhile, a major share increase passed. What does this mean?

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Brixton Metals secures nearly $10M in a complex financing deal. Here’s why this capital is a game-changer for its flagship Thorn copper-gold project.